tldrdailynews.com logo

Beam Therapeutics Faces Setback in CRISPR Trial Amid Financial Updates

1 min read
Source: STAT
Beam Therapeutics Faces Setback in CRISPR Trial Amid Financial Updates
Photo: STAT
TL;DR

A patient with sickle cell disease died from respiratory failure during a clinical trial of Beam Therapeutics' CRISPR-based treatment, BEAM-101. The death, attributed to chemotherapy preparation for the gene editing therapy, raises concerns despite early promising results. This was the first death among six participants in the trial.

Topics:businesshealth#beam-therapeutics#clinical-trial#crispr#gene-editing#health#sickle-cell-disease
Share this article
  1. Patient dies in Beam Therapeutics trial of CRISPR sickle cell treatment  STAT
  2. Beam Therapeutics's Earnings: A Preview  Benzinga
  3. Beam Therapeutics to Present Data Across Hematology  GlobeNewswire
  4. Beam Therapeutics Inc Reports Q3 2024 EPS of $1.17, Revenue of $14.27 Million, Slightly Missing Estimates  GuruFocus.com
  5. Beam Therapeutics to present data on BEAM-101, BEAM-201 at ASH meeting  TipRanks

Want the full story? Read the original reporting

Read on STAT